Regulation of faecal biomarkers in inflammatory bowel disease patients treated with oral mastiha (Pistacia lentiscus) supplement: A double‐blind and placebo‐controlled randomised trial

Abstract

Funding information ENOSI MASTIHOPARAGWGWN CHIOUThere is a keen research upon the effects of nutraceuticals on inflammatory bowel disease. The purpose of this study was to explore the effect of mastiha supplement, rich in bioactive nutraceuticals, in active inflammatory bowel disease. This is a randomised, double-blind, placebo-controlled clinical trial. Α total of 60 inflammatory bowel disease patients were enrolled and randomly allocated to mastiha (2.8 g/day) or placebo groups for 3 months adjunct to stable medical treatment. Medical and dietary history, Inflammatory Bowel Disease Questionnaire (IBDQ), Harvey-Bradshaw index, partial Mayo score, biochemical indices, faecal, and blood inflammatory markers were assessed. A clinically important difference between groups in IBDQ was defined as primary outcome. Inflammatory Bowel Disease Questionnaire score significantly improved in verum compared with baseline (p = 0.004).There was a significant decrease in faecal lysozyme in mastiha patients (p = 0.018) with the mean change being significant (p = 0.021), and significant increases of faecal lactoferrin (p = 0.001) and calprotectin (p = 0.029) in the placebo group. Fibrinogen reduced significantly (p = 0.006) with a significant mean change (p = 0.018), whereas iron increased (p = 0.032) in mastiha arm. Our results show regulation of faecal lysozyme by mastiha supplement adjunctive to pharmacological treatments in active inflammatory bowel disease. An effect secondary to a prebiotic potency is proposed.

Antioxidative Efficacy of a Pistacia Lentiscus Supplement and Its Effect on the Plasma Amino Acid Profile in Inflammatory Bowel Disease: A Randomised, Double-Blind, Placebo-Controlled Trial

“…Another interesting result of the present study was the significant reduction in the ratios of oxLDL/LDL and oxLDL/HDL in the PL arm compared with the placebo arm. A decrease in feacal lysozyme in the PL arm has been reported in the study of Papada and coworkers [ 29 ], and this parallels the decrease in the oxLDL/LDL and oxLDL/HDL ratios. Herein, when changes in oxidative stress were assessed separately for CD and UC patients, significant changes were reported for patients with CD, showing possibly a most promising response to this antioxidant supplement in CD compared with UC.…”

“…In previous research, it has been reported that a 3-month intervention with a supplement containing the natural resinous product of Pistacia lentiscus (the supplement herein given as PL), adjunctive to stable medical treatment, regulated faecal biomarkers and improved quality of life in active IBD patients compared with a placebo [ 29 ]. Herein, the aim was to explore the effects of this intervention on biomarkers of oxidative stress in active IBD.…”

More than a common acid buffering in the treatment of Non-Erosive GERD-like Clinical Spectrum: A Chios Masthia-based Formulation with (Cyto) Protecting Effect

“…Besides other minor excipients, the main ingredients of a novel phytoformula, (DOGDG-121, Refl umed, named, Italy) are chios masthia and banana. The healing properties of chios masthia against ulcer and gastritis date back in the middle 1980's [9,10] and a more recent study [11][12][13][14][15][16][17], suggested that arabinogalactan-proteins (AGP's) isolated by mastic could display some moderate anti-H.pylori activity, given his reported bactericidal activity in vitro [12].…”

“…As for its anti-infl ammatory gastrointestinal properties, already in 2007, Kaliora et al [14,15], demonstrated that mastic administration in patients with active Crohn's disease (CD) signifi cantly reduced the CD activity index, plasma interleukin-6 and C-reactive protein levels while also recovering a normal total antioxidant potential. A properly done double-blind, placebo-controlled clinical study in this setting has been very recently published [16][17][18][19][20][21][22]. A minor biological ingredient of DOGDG-121, is a fl avonoid-rich banana (i.e.…”

“…those in whom the characteristic symptoms better parallel the extent of acid exposure of lower oesophageal mucosa. However, a relevant number of NERD patients show only a limited acid over-exposure and this clarifi es the modest symptomatic benefi t to PPI as compared to those patients with erosive esophagitis[31][32][33]. What seems evident so far is that most of NERD patients will never develop erosive esophagitis In this study Miwa et al, found no statistically signifi cant differences between histological markers of esophagitis, the percentage of acid exposure of the lower oesophagus, or the number of gastric acid refl ux episodes between refl ux oesophagitis and NERD patients.Interestingly, they found out a signifi cant increase in the mean number of nerve fi bers in the NERD group compared to the refl ux oesophagitis.…”